Phreesia Inc

Phreesia Inc(PHR)の株式分析

$10.940

-0.100 (-0.91%)終値時点

Loading chart…
高値
11.350
始値
11.170
出来高加重平均価格
11.06
出来高
655.03K
時価総額
1.21B
安値
10.895
売買代金
7.25M
EV/EBITDA(TTM)
9.92

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

www.phreesia.com

AI分析 of Phreesia Inc (PHR)

中立

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

バリュエーション指標

Phreesia Inc(PHR)の現在の予想PERは12.02で、5年平均は3.87です。

予想PER

適正
5年平均 P/E
3.87
現在のP/E
12.02
割高
193.08
割安
-185.35

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-21.64
現在のEV/EBITDA
9.92
割高
98.21
割安
-141.48

予想PSR

割安
5年平均 P/S
3.63
現在のP/S
1.28
割高
5.97
割安
1.29

Alphio AI による PHR の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%PHR

$23.17

シナリオ価格

基

基本

基本 · 50%PHR

$22.64

シナリオ価格

弱

弱気

弱気 · 25%PHR

$21.67

シナリオ価格

PHR を保有するクジラ

P

Pale Fire Capital SE

+ を保有PHR

-2.45%

3か月リターン

イベントタイムライン

2026-09-02 (ET)

19:30:00

Major Indices Bounce Back as ADP Employment Data Falls Short

16:30:00

Phreesia Reports Q2 Revenue of $129.5M, Beating Expectations

2026-06-11 (ET)

14:30:00

Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B

2026-05-27 (ET)

19:50:00

WTI Crude Oil Falls Below $90, Energy Sector Worst Performer

16:30:00

Phreesia Up 12% to $10.21 After Q1 Results, Affirms Guidance

ニュース

PHR のよくある質問 — Alphio AI が回答

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める